<DOC>
	<DOCNO>NCT02597400</DOCNO>
	<brief_summary>This Phase 1 , open-label , sequential , multiple-dose , drug-drug interaction study GK activator HMS5552 metformin patient type 2 diabetes mellitus ( T2DM ) .</brief_summary>
	<brief_title>Drug-Drug Interaction Study Glucokinase Activator HMS5552 Metformin T2DM</brief_title>
	<detailed_description>This Phase 1 , open-label , sequential , multiple-dose , drug-drug interaction study GK activator HMS5552 metformin patient type 2 diabetes mellitus ( T2DM ) . The study assess potential pharmacokinetic interaction HMS5552 metformin subject T2DM . The study also evaluate safety tolerability HMS5552 simultaneous administration metformin subject T2DM .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Male and/or female subject age 18 70 year Body Mass Index ( BMI ) approximately 22 38kg/m2 HbA1c ≥7 % ≤12 % Are capable give informed consent comply study procedure fast blood glucose ≤110 ≥270mg/dL Type 1 diabetes mellitus , latent autoimmune diabetes adult History symptom clinically significant cardiovascular disease , particularly coronary artery disease , arrhythmia , atrial tachycardia , congestive heart disease within one year screen History liver disease clinically significant renal disease Known hypersensitivity metformin hydrochloride ; Positive pregnancy test result ;</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>